Pharmacological interventions for preventing post-traumatic stress disorder (PTSD)

Area of Science:

• Pharmacology
• Psychiatry
• Clinical Trials

Background:

• Post-traumatic stress disorder (PTSD) is a significant mental health condition following traumatic events.
• Early pharmacological interventions may reduce the risk of developing PTSD.
• Evidence for the efficacy of these interventions requires systematic evaluation.

Purpose of the Study:

• To evaluate the effectiveness of pharmacological treatments for preventing PTSD in adults after trauma.
• To synthesize findings from randomized controlled trials (RCTs) comparing pharmacological agents to placebo.

Main Methods:

• Searched major databases (CENTRAL, EMBASE, MEDLINE, PsycINFO) and clinical trial registries for relevant RCTs.
• Included studies comparing pharmacological interventions with placebo for PTSD prevention in adults.
• Two independent reviewers assessed eligibility, extracted data, and evaluated the risk of bias.

Main Results:

• Nine RCTs (345 participants) were included, investigating hydrocortisone, propranolol, escitalopram, temazepam, and gabapentin.
• Moderate quality evidence suggests hydrocortisone is effective in preventing PTSD onset (RR 0.17, 95% CI 0.05 to 0.56).
• Low quality evidence did not support propranolol, and single trials found no efficacy for escitalopram, temazepam, or gabapentin; most studies had a high risk of bias.

Conclusions:

• Hydrocortisone demonstrates moderate evidence for preventing PTSD development in adults.
• No evidence supports the use of propranolol, escitalopram, temazepam, or gabapentin for PTSD prevention.
• Findings are limited by small study sizes and methodological issues, necessitating further research.